Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases

被引：20

作者：

Pinter, Andreas ^{[1
]}

Wilsmann-Theis, Dagmar ^{[2
]}

Peitsch, Wiebke K. ^{[3
]}

Moessner, Rotraut ^{[4
]}

机构：

[1] Univ Hosp Frankfurt Main, Dept Dermatol Venereol & Allergol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany

[2] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany

[3] Vivantes Klinikum Friedrichshain, Dept Dermatol & Phlebol, Berlin, Germany

[4] Univ Clin Gottingen, Dept Dermatol Venereol & Allergol, Gottingen, Germany

来源：

JOURNAL OF DERMATOLOGY | 2019年 / 46卷 / 05期

基金：

澳大利亚研究理事会;

关键词：

brodalumab; interleukin-17; A; interleukin-17 receptor A; palmoplantar pustular psoriasis; pustulosis palmoplantaris; PLAQUE PSORIASIS; EFFICACY; SAFETY; IXEKIZUMAB;

D O I：

10.1111/1346-8138.14815

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Palmoplantar pustular psoriasis, also termed palmoplantar pustulosis (PPP), is a rare disease affecting the palmoplantar regions characterized by sterile, yellow to brown pustules mostly on erythematous skin. PPP is related to a high burden due to painful, impaired and stigmatizing character. Several isoforms of interleukin (IL) have been implicated in its pathophysiology. Here, we report on four patients with PPP treated with the novel IL-17 receptor A blocker brodalumab, in whom this therapy was not successful or showed moderate improvement combined with adverse events.

引用

页码：426 / 430

页数：5

共 11 条

[1] Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders [J].

Balato, Anna ;

Scala, Emanuele ;

Balato, Nicola ;

Caiazzo, Giuseppina ;

Di Caprio, Roberta ;

Monfrecola, Giuseppe ;

Raimondo, Annunziata ;

Lembo, Serena ;

Ayala, Fabio .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (11) :1363-1374

[2] No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis [J].

Bokor-Billmann, Therezia ;

Schaekel, Knut .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (03) :216-220

[3] Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies [J].

Georgakopoulos, Jorge R. ;

Phung, Michelle ;

Ighani, Arvin ;

Yeung, Jensen .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (01) :155-157

[4] Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study [J].

Imafuku, Shinichi ;

Honma, Masaru ;

Okubo, Yukari ;

Komine, Mayumi ;

Ohtsuki, Mamitaro ;

Morita, Akimichi ;

Seko, Noriko ;

Kawashima, Naoko ;

Ito, Saori ;

Shima, Tomohiro ;

Nakagawa, Hidemi .

JOURNAL OF DERMATOLOGY, 2016, 43 (09) :1011-1017

[5]

Mrowietz U, 2018, SECUKINUMAB TREATMEN, pP1855

[6] Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum [J].

Murakami, Masamoto ;

Hagforsen, Eva ;

Morhenn, Vera ;

Ishida-Yamamoto, Akemi ;

Iizuka, Hajime .

EXPERIMENTAL DERMATOLOGY, 2011, 20 (10) :845-847

[7] Successful treatment of palmoplantar pustular psoriasis with brodalumab [J].

Nakao, Momoko ;

Asano, Yoshihide ;

Kamata, Masahiro ;

Yoshizaki, Ayumi ;

Sato, Shinichi .

EUROPEAN JOURNAL OF DERMATOLOGY, 2018, 28 (04) :538-539

[8] Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis [J].

Saeki, H. ;

Nakagawa, H. ;

Ishii, T. ;

Morisaki, Y. ;

Aoki, T. ;

Berclaz, P. -Y. ;

Heffernan, M. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (06) :1148-1155

[9] Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis [J].

Takahashi, Hidetoshi ;

Sato, Katsuhiko ;

Takagi, Akiyoshi ;

Iizuka, Hajime .

JOURNAL OF DERMATOLOGY, 2018, 45 (11) :E325-E326

[10]

Wilsmann-Theis Dagmar, 2017, Dermatol Online J, V23

← 1 2 →